(MVR) and pericardial patch closure of ASD secundum with cardiopulmonary bypass (CPB), the patient preferred non-surgical interventional method of treatment. So she was treated with Percutaneous Trans-luminal Mitral valve Commusurotomy (PTMC) followed by Transcatheter closure of ASD.
Under local anesthesia, right femoral vein was punctured and a 6F sheath was introduced. Firstly, PTMC was done. Then ASD was closed with an Amplatzer device under transthoracic echocardiographic guidance.The patient was given Antibiotic for 5 days & Aspirin 75 mg daily for six months. She was discharged on 3 rd day with followup advice at 1, 3, 6 & 12 months. After the procedure, the patient attended two follow-up visits & found quite free of symptoms. Echo follow-up showed no residual shunt across ASD device & transmitral gradient was PPG -7 mmHg & MPG-5mmHg, indicating absolutely near normal.
Discussion:
The original case of Lutembacher syndrome was a female of 61 years old who had been pregnant for 7 times. Female preponderance is seen in both ASD & MS, and thus Lutembacher syndrome has a predilection for female. 1, 2 The incidence of MS in ASD is 4% and conversely the incidence of ASD in patients with MS is 0.6-0.7%. 7 The hemodynamic effects of these coexisting ASD & MS is different from that of isolated ASD or MS. MS augments left to right shunting through ASD, while the nonrestrictive ASD decompreses the left atrum reducing the diastolic mitral gradient. 8 The pressure half time method consistently overestimates the mitral valve area. The extent of overestimation is greater in patient with larger ASD. The hemodynamic pressure half time is independent of the mitral valve area, chamber compliance and peak trans-mitral gradient. 7 Survival to advanced age has also been reported in another instance; an 81 years old woman experienced no symptoms related to her heart disease until she reached 75 years of age. 13 These favorable reports, however, should not obscure the fact that the long-term natural history of ASD is unfavorably influenced by MS, which augments the left to right shunt and predisposes to atrial fibrillation and right ventricular failure. 14 So, if patient is diagnosed at late stage, pulmonary hypertension and heart failure develops and the prognosis is bad. 15 Previously, surgical treatment with cardiopulmonary by pass (CPB) was the gold standard method of treating Lutembacher syndrome. But with the advent of transcatherter ASD device closure particularly the Amplatzer Septal Occuluder & PTMC with Inoue balloon technique, now a days, surgery is replaced by this non-surgical method with lot of advantages. These include, avoidance of complications associated with open heart surgery particularly during cardiopulmonary bypass, general anesthesia, hazards of blood transfusion, quicker recovery with a short hospital stay. 2 But the only disadvantage is that in case of restenosis of mitral valve, repeat trans-septal puncture would not be possible but that can even be possible by trans-arterial retrograde non-trans-septal technique in which entry into the left atrium is achieved via the left ventricle, or one can go for surgery either CMC or MVR whatever indicated. 16 There are few experiences with Transcatheter treatment of Lutembacher syndrome. [2] [3] [4] [5] [6] 17 The use of percutaneous treatment of the Lutembacher syndrome was first described by . Combined umbrella closure of ASD with Lock's Clamsher occluder in conjunction with mitral and aortic balloon valvotomies was carried out with single balloon valvotomy & double balloon for mitral valvotomy as a palliative rescue procedure in 43 year-old female and severe pulmonary hypertension to improve the risk prior to surgical repair. After wards, she refused surgery and died suddenly a few weeks later. With the advent of Amplatzer Septal Occluder (ASO), the first successful Transcatheter therapy of Lutembacher's syndrome was described by Joseph et al. 17 Currently, the Inoue balloon is most widely used for mitral vavuloplasty and Amplatzer Septal Occluder (ASO) is used for percutaneous ASD closure. The successful combined use of these two devices was described by Chau et al. 18 We performed device closure of ASD under TTE guidance & local anaesthesia. The advantages of percutaneous correction over surgical correction includes the avoidance of complications of open heart surgery, quick recovery and short hospital stay, but if patient develops mitral valve restenosis, either surgery or retrograde percutaneous therapy would be required.
Conclusion:
Non-surgical Transcatheter treatment of Lutembacher Syndrome is a safe procedure if the lesions are suitable for intervention avoiding invasive open heart surgery.
